Physician profile
Mohammed Moosa
NPI 1437268620
$3,727.82
in general payments reported to CMS, 2019-2025
23 companies · $330 in 2025
The $330 reported for 2025 was more than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $711 · 2020: $627 · 2021: $879 · 2022: $383 · 2023: $441 · 2024: $357 · 2025: $330.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,109 · Education: $19.81.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,108.70 |
| Education | $19.81 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals Lp | $680.69 | 2019-2025 | Farxiga, Airsupra |
| Sanofi-Aventis U.S. LLC | $553.73 | 2019-2023 | |
| Lilly USA, LLC | $353.10 | 2019-2025 | Mounjaro, Jardiance, Zepbound |
| Novo Nordisk INC | $335.64 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Glaxosmithkline, LLC. | $279.59 | 2021-2025 | Trelegy Ellipta |
| Abbott Laboratories | $201.58 | 2021-2024 | Freestyle Libre 3 |
| Pfizer INC. | $194.03 | 2019-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $185.07 | 2020-2022 | |
| Novartis Pharmaceuticals Corporation | $184.57 | 2019-2021 | |
| Amgen INC. | $167.09 | 2019-2025 | Otezla, Repatha, Repatha |
| Exact Sciences Corporation | $139.41 | 2023-2025 | The Cologuard Plus Collection Kit, Cologuard Collection Kit |
| Amarin Pharma, INC. | $73.38 | 2019-2020 | |
| Corcept Therapeutics | $66.11 | 2024-2025 | Korlym |
| Mannkind Corporation | $59.40 | 2022 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $49.02 | 2019-2021 |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $37.94 | 2020-2023 | Belsomra |
| Janssen Pharmaceuticals, INC | $34.39 | 2019 | |
| Ge Healthcare | $26.32 | 2023 | |
| Idorsia Pharmaceuticals US INC | $24.80 | 2023 | Quviviq |
| Intra-Sana Laboratories | $24.25 | 2024 | Reltone 400 Mg, Reltone 200 Mg, Glycate |
| Abbvie INC. | $23.14 | 2023 | |
| Biohaven Pharmaceutical Holding Company Ltd. | $19.73 | 2022 | |
| Allergan, INC. | $14.84 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mohammed Moosa listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.